PubMed · 2016 · 45 citations · 38 references
MedicineOncologyPharmacologyCancer GeneticsMolecular OncologyOncogenesApoptosis ResistanceMalignant NeoplasmsMolecular Tumor ProfilingOncogenic Signaling PathwaysOvarian CancerTargeted Cancer TherapyCell Viability AssaysCopy Number Variation HeterogeneityErk SignalingMek InhibitionMek InhibitorsOvarian Cancer Clinical TrialsOvarian Cancer TreatmentWestern Blotting
mutations, were highly sensitive to MEKi. Drug anti-proliferative efficacy correlated with the degree of inhibition of ERK phosphorylation, with trametinib being the most potent agent. Differences in MEKi efficacy were observed in LGSC cell lines. Trametinib showed the greatest anti-proliferative effects. This study serves as a basis for much needed future research on MEKi drug efficacy in LGSC.
38
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Corine M. Beaufort, Jean Helmijr, Anna Piskorz et al. · PLoS ONE · 2014 · 414 citations · Full text